Status and phase
Conditions
Treatments
About
The aim of the study is to assess the safety and tolerability of increasing doses of ATOR-1017 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Major Inclusion Criteria:
A patient is eligible to be included in the study if all the following criteria apply:
Major Exclusion Criteria:
A patient is excluded if any of the following criteria apply:
Primary purpose
Allocation
Interventional model
Masking
27 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal